## **Core Concept**
Chronic Myeloid Leukemia (CML) is a type of cancer that affects the white blood cells and tends to progress slowly over time. It is characterized by the uncontrolled growth of myeloid cells in the bone marrow. A specific chromosomal abnormality is hallmark to this condition.

## **Why the Correct Answer is Right**
The correct answer, , refers to a specific chromosomal translocation known as the Philadelphia chromosome. This abnormality results from a reciprocal translocation between chromosome 9 and chromosome 22, denoted as t(9;22)(q34;q11). The translocation leads to the fusion of the BCR (Breakpoint Cluster Region) gene on chromosome 22 with the ABL1 gene on chromosome 9, creating the BCR-ABL1 fusion gene. This fusion gene produces a tyrosine kinase enzyme that is always active and leads to uncontrolled cell division, which is a key factor in the development of CML.

## **Why Each Wrong Option is Incorrect**
- **Option A:** - This option does not accurately represent the specific translocation associated with CML.
- **Option B:** - While this involves chromosomes 9 and 22, the description does not accurately reflect the nature of the Philadelphia chromosome translocation.
- **Option D:** - This option does not correctly represent the translocation associated with CML.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that the presence of the Philadelphia chromosome, resulting from the t(9;22) translocation, is not only diagnostic for CML but also for a subset of acute lymphoblastic leukemia (ALL) cases. The development of tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 fusion protein has revolutionized the treatment of CML, making it a model for targeted therapy in cancer.

## **Correct Answer:** .